[HTML][HTML] Zolpidem and driving impairment—identifying persons at risk
RH Farkas, EF Unger, R Temple - New England journal of …, 2013 - Mass Medical Soc
RH Farkas, EF Unger, R Temple
New England journal of medicine, 2013•Mass Medical SocBecause of new findings about next-day somnolence and sex differences in zolpidem
clearance, the FDA has recommended lower doses of the drug, particularly for women, and
emphasizes the greater risk of impairment with modified-release than with immediate-
release formulations.
clearance, the FDA has recommended lower doses of the drug, particularly for women, and
emphasizes the greater risk of impairment with modified-release than with immediate-
release formulations.
Because of new findings about next-day somnolence and sex differences in zolpidem clearance, the FDA has recommended lower doses of the drug, particularly for women, and emphasizes the greater risk of impairment with modified-release than with immediate-release formulations.
The New England Journal Of Medicine